CN1254255C - Oral liquor for curing cerebral hemorrhage and its preparation method by using leach - Google Patents
Oral liquor for curing cerebral hemorrhage and its preparation method by using leach Download PDFInfo
- Publication number
- CN1254255C CN1254255C CN 03107815 CN03107815A CN1254255C CN 1254255 C CN1254255 C CN 1254255C CN 03107815 CN03107815 CN 03107815 CN 03107815 A CN03107815 A CN 03107815A CN 1254255 C CN1254255 C CN 1254255C
- Authority
- CN
- China
- Prior art keywords
- hirudo
- cerebral hemorrhage
- medicinal liquid
- radix
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an oral medicinal liquid prepared from leech and used for treating cerebral hemorrhage and a preparation method thereof. The oral medicinal liquid is composed of the following components by weight ratio: 6 of leech, 1 of notoginseng and 2 of rhubarb. The present invention has the advantages that the medicines are sieved scientifically in view of treatment on cerebral hemorrhage of modern medicine; the product has the efficacy of activating blood circulation to dissipate blood stasis and promoting absorption of intracranial hematoma; the time for absorbing hematoma is advanced, and daily blood absorption amount is obviously higher than that of people do not taking the oral medicinal liquid. The oral medicinal liquid has a very good effect on patients suffering from hematoma attacking the ventricle, and is particularly suitable for the acute stage of cerebral hemorrhage. The oral medicinal liquid has the advantages of high therapeutic effect, no toxic and side effect, affirmative medicinal effect and little damage to neurological function. In addition, the oral medicinal liquid promotes restoration of the neurological function and reduces mortality, the total effective rate for treatment can reach 95%, and thus, the oral medicinal liquid has very important significance on treating cerebral hemorrhage.
Description
Affiliated field
The present invention relates to a kind of medicine for the treatment of cerebral hemorrhage, especially treat the oral liquid and the compound method thereof of cerebral hemorrhage with the Hirudo preparation.
Background technology
Cerebral hemorrhage is one of current multiple disease of generally acknowledging both at home and abroad, and Chinese traditional method generally adopts dehydrant to reduce intracranial pressure, nourishing brain cell, anti symptom treatment.Have no way for the treatment of as for hematoma itself, can only wait for that nature absorbs, and the good medicine that is of no curative effect at present is in advance with treatment.
Summary of the invention
The objective of the invention is to be problem, and provide a kind of with Hirudo preparation treatment cerebral hemorrhage oral liquid and compound method thereof at above-mentioned existence.For fundamentally solving the hematoma problem, promote that hematoma absorbs as early as possible, support the infringement of hematoma surrounding health tissue, the present invention has adopted activating blood and removing stasis Method that the cerebral hemorrhage disease is effectively treated.It is to adopt motherland's theory of Chinese medical science, through the rich experiences of practical application, screens the prescription that pure Chinese medicine is made, and through science processing, refinement, makes it be applicable to treatment cerebral hemorrhage disease, and evident in efficacy.This product also can be made into dosage forms such as oral liquid or granule.。
The object of the present invention is achieved like this:
It is formulated by following component (by weight):
Hirudo: Radix Notoginseng: Radix Et Rhizoma Rhei=6: 1: 2
Preparation method of the present invention is:
The trematodiasis of fetching water according to the above ratio is ground into coarse powder, does to carry out percolation after solvent impregnated 24 hours with 50% ethanol, and flow velocity 2ml/min collects the 15 times of amounts of liquid of filtering, and concentrating under reduced pressure is put to room temperature again, and 3000r/min is centrifugal, and it is standby to get supernatant; Get Radix Notoginseng according to the above ratio, Radix Et Rhizoma Rhei powder is broken into coarse powder, adds 60% alcohol reflux secondary, for the first time 8 times of amount solvents are 2.5 hours, 5 times of amount solvents are 1.5 hours for the second time, merge ethanol extract, reclaim ethanol and concentrated, 3000r/min is centrifugal, supernatant and Hirudo liquid are merged, placed 48 hours, in 0 ℃ of-10 ℃ of cold preservation, centrifugal 3000r/min gets supernatant and adds correctives, antiseptic, adds water, stir evenly, leave standstill, filter, fill, sterilization, promptly.
Advantage of the present invention is: at modern medicine screening of medicaments to the treatment of cerebral hemorrhage disease and scientifically, its product has the blood circulation promoting and blood stasis dispelling function, be particularly useful for Acute Cerebral Hemorrhage, and curative effect height, have no side effect, drug effect is treated total effective rate and is reached 95% certainly, therefore the treatment cerebral hemorrhage is had extremely important meaning.
No valuable product among the present invention, used Chinese medicine source is sufficient, no in great shortage, and its preparation technology is easy to grasp, and that obeys is safe and reliable, has no side effect, and the curative effect height is easy to apply.
The invention has the beneficial effects as follows: have blood stasis alive, hemorrhage, removing heat by catharsis expells the pathogenic heat only, promote the effect of intracranial hematoma absorption; Can make the absorption of hematoma time in advance, and daily the amount of sucking blood is apparently higher than refusing to obey this medicine person, especially excellent to patient's effect of going into the ventricles of the brain, absorption of hematoma is complete, and nervous function damage is little, has promoted the recovery of function of nervous system, reduces mortality rate.
This paper is from toxicological experiment, pharmacological action, and clinical case is observed the further practicality and the creativeness of this method of proof.
Provide toxicity, pathological replacement by Liaoning Prov. Thrombus Disease Chinese-Western Medical Combined Therapeutic Cen's institute.
One, compound recipe Hirudo oral liquid chmice acute toxicity test:
Laboratory animal: Kunming mouse is provided the quality certification number by Traditional Chinese Medicinal College of Liaoning's Experimental Animal Center: No. 002, the real moving word of the Liao Dynasty.
Be subjected to the reagent thing: compound recipe Hirudo oral liquid is analyzed teaching and research room by Traditional Chinese Medicinal College of Liaoning's department of Chinese materia medica Chinese medicine and is provided.
Get 40 of body weight 18-22g mices, male and female half and half are divided into the blank group at random, fasting experimentized after 16 hours, the administration group is irritated stomach by the dosage of 0.4ml/10g and is given compound recipe Hirudo oral liquid, the dosage gastric infusion of pressing 0.4ml/10g after 5 hours again once, twice totally.Meanwhile the blank group is irritated stomach and is given consubstantiality hydrops, observes after the administration and raises seven days, and the record mouse toxicity reacts and death condition, and observes the variation of its main organs and tissue.
Conclusion:
Compound recipe Hirudo oral liquid extractum is under the situation of Cmax 300g/ml that can prepare (containing the crude drug amount) and maximum volume 0.4ml/10g administration, be administered twice to mouse stomach in one day, none is only dead for mice, except that slight loose stool symptom is arranged, do not see that other toxic reaction takes place, administration was put to death mice after seven days, dissected, and observed main organs such as its heart, liver, lung, kidney and organized no abnormality seen.
Two, compound recipe Hirudo oral liquid long term toxicity test:
Laboratory animal: the Wistar rat, body weight 80-130g is provided by Traditional Chinese Medicinal College of Liaoning's Experimental Animal Center, the quality certification number: No. 002, the real moving word of the Liao Dynasty.
Be subjected to the reagent thing: compound recipe Hirudo oral liquid is analyzed teaching and research room by Traditional Chinese Medicinal College of Liaoning's department of Chinese materia medica Chinese medicine and is provided.
Reagent: lot number M002224 is provided by U.S. Beckman company.
Get body weight 80-130g, 60 of Wistar rats are divided into three groups of high and low dose group and blank groups at random by the body weight size, and 20 every group, male and female half and half, high and low dose group are all by the capacity gastric infusion of 1ml/100g, successive administration 90 days; The blank group is given the distilled water of the capacity of grade every day, every then treated animal is put to death 14 (about 2/3), become celestial each organs and tissues of animal is carried out perusal, and organs such as the heart, liver, spleen, lung, kidney, adrenal gland, thymus are done the pathology inspection, remaining animal is normal to be raised for two weeks, carried out convalescent period and observed.
Conclusion:
1, feed during each treated animal is tried, drinking-water, defecation are all normal, motion healthy active, by a hair gloss, find dead and other ANOMALOUS VARIATIONS.
2, each treated animal body weight gain is normal, and administration group and matched group be there was no significant difference (P＞0.05) relatively.
3, experiment each treated animal hepatic and renal function of back and serum biochemistry measurement result and matched group compare there was no significant difference.
4, experiment each treated animal hemogram checking of back and matched group compare there was no significant difference.
5, each treated animal heart, liver, spleen, lung, kidney, adrenal gland, thymus outward appearance and its organ index there are no significant difference.
6, each treated animal is the same with matched group, the size and form of organs such as the heart, liver, spleen, lung, kidney is normal substantially, smooth surface, no hemorrhage, adhesion or necrosis, histological examination is respectively organized internal organs and be there is no organic disease, cardiac muscle fiber does not have degeneration or necrosis, and structure is normal, and lung tissue and spleen are organized also no abnormality seen change, the all no abnormal changes of structure such as hepatocyte and glomerule, renal tubules, promptly relevant with drug metabolism important organ does not all have obvious change.
7, remaining animal is normal raised for 2 weeks, and the animal general state is normal, put to death after each internal organs outward appearance of perusal and main organs carried out histological examination, and no abnormality seen changes.
Three, be the clinical effectiveness situation of compound recipe Hirudo oral liquid below:
Provide the clinical experiment report by Liaoning Prov. Thrombus Disease Chinese-Western Medical Combined Therapeutic Cen.
Choose cerebral hemorrhage clinical case totally 200 examples, it is divided into treatment group, each 100 example of matched group at random, two groups are all adopted Comprehensive Treatment, reduce intracranial pressure, control cerebral edema, nourishing brain cell, prevent and treat complication.The treatment group adds compound recipe Hirudo oral liquid 2.1g on this basis, three times on the one, warm water delivery service, or gavage, can take after the morbidity, the 14th day check head CT after the medication, the 28th day or carry out the scoring of nervous function damage improvement degree when leaving hospital, to observe absorption of hematoma situation and efficacy evaluation (referring to table 1).
Conclusion
From above clinical observation result, treatment group total effective rate 93%, obvious effective rate 57%, matched group total effective rate 85%, obvious effective rate 54% illustrates that treatment group curative effect is better than matched group.And the treatment group daily absorbs blood volume apparently higher than matched group, proved that also this medicine is to promoting that hematoma absorbs as early as possible, the infringement of supporting hematoma surrounding health tissue has obvious curative effects, and after the medication liver, renal function there is not influence, safe and reliable, have no side effect, drug effect is sure, be convenient to take, especially excellent to patient's effect of people's ventricles of the brain.
Function: the blood stasis of living, hemorrhage, removing heat by catharsis expells the pathogenic heat only promote intracranial hematoma to absorb.
Cure mainly: be used for Acute Cerebral Hemorrhage.
Describe the present invention in detail below in conjunction with embodiment:
The specific embodiment:
Embodiment 1:
It is formulated by following component (by weight):
Hirudo: Radix Notoginseng: Radix Et Rhizoma Rhei=6: 1: 2
The trematodiasis 300g that fetches water according to the above ratio is ground into coarse powder, makes after solvent impregnated 24 hours percolation in accordance with the law with 50% ethanol, and flow velocity 2ml/min collects the liquid 4500ml that filters, and is evaporated to 700ml, puts to room temperature, and 3000r/min is centrifugal, and it is standby to get supernatant; Other gets Radix Notoginseng 50g, Radix Et Rhizoma Rhei 100g is ground into coarse powder, adds 60% alcohol reflux secondary, measures solvent 2.5 hours for 8 times for the first time, measured solvent 1.5 hours for 5 times for the second time, merge ethanol extract, reclaim ethanol and also be concentrated into 3000ml, 3000r/min is centrifugal, and supernatant and Hirudo liquid merge, and place 48 hours, in 5 ℃ of cold preservations, centrifugal 3000r/min gets supernatant and adds people's correctives, antiseptic, adds water to 1000ml, stir evenly, leave standstill, filter, fill, sterilization, promptly.
Embodiment 2:
It is formulated by following component (by weight):
Hirudo: Radix Notoginseng: Radix Et Rhizoma Rhei=6: 1: 2
The trematodiasis 900g that fetches water according to the above ratio is ground into coarse powder, makes after solvent impregnated 24 hours percolation in accordance with the law with 80% ethanol, and flow velocity 2ml/min collects the liquid 13500ml that filters, and is evaporated to 2100ml, puts to room temperature, and 3000r/min is centrifugal, and it is standby to get supernatant; Other gets Radix Notoginseng 150g, Radix Et Rhizoma Rhei 300g is ground into coarse powder, adds 40% alcohol reflux secondary, measures solvent 3 hours for 7 times for the first time, measures solvent 2 hours for 3 times for the second time, merge ethanol extract, reclaim ethanol and be concentrated into 900ml, 3000r/min is centrifugal, supernatant and Hirudo liquid merge, and place 48 hours, in 10 ℃ of cold preservations, centrifugal 3000r/min gets supernatant, adds correctives, antiseptic, adds water to 3000ml, stir evenly, leave standstill, filter, fill, sterilization, promptly.
Embodiment 3:
It is formulated by following component (by weight):
Hirudo: Radix Notoginseng: Radix Et Rhizoma Rhei=6: 1: 2
The trematodiasis 1500g that fetches water according to the above ratio is ground into coarse powder, makes after solvent impregnated 24 hours percolation in accordance with the law with 50% ethanol, and flow velocity 2ml/min collects the liquid 67500ml that filters, and is evaporated to 3500ml, puts to room temperature, and 3000r/min is centrifugal, and it is standby to get supernatant; Other gets Radix Notoginseng 250g, Radix Et Rhizoma Rhei 500g is ground into coarse powder, adds 60% alcohol reflux secondary, measures solvent 2 hours for 11 times for the first time, measured solvent 1 hour for 7 times for the second time, merge ethanol extract, reclaim ethanol and also be concentrated into 1500ml, 3000r/min is centrifugal, and supernatant and Hirudo liquid merge, and place 48 hours, in 2 ℃ of cold preservations, centrifugal 3000r/min gets supernatant and adds correctives, antiseptic, adds water to 5000ml, stir evenly, leave standstill, filter, fill, sterilization, promptly.
Table 1 absorption of hematoma situation and efficacy evaluation table
| Group | Be almost recovered | Marked improvement | Progressive | No change | Worsen | Dead |
| The treatment group | 31 | 26 | 36 | 5 | 1 | 1 |
| Matched group | 30 | 24 | 31 | 10 | 2 | 3 |
Claims (2)
1, a kind of oral liquid with Hirudo preparation treatment cerebral hemorrhage is characterized in that it is formulated by weight by following component:
Hirudo: Radix Notoginseng: Radix Et Rhizoma Rhei=6: 1: 2
2, a kind of oral liquid compounding method with Hirudo preparation treatment cerebral hemorrhage is characterized in that:
In Hirudo: Radix Notoginseng: the ratio water intaking trematodiasis of Radix Et Rhizoma Rhei=6: 1: 2 is ground into coarse powder, makes to carry out percolation after solvent impregnated 24 hours the flow velocity 2ml/min collection 15 times of amounts of liquid of filtering with 50% ethanol, concentrating under reduced pressure again, put to room temperature, 3000r/min is centrifugal, and it is standby to get supernatant; In Hirudo: Radix Notoginseng: the ratio of Radix Et Rhizoma Rhei=6: 1: 2 is got Radix Notoginseng, Radix Et Rhizoma Rhei powder is broken into coarse powder, adds 60% alcohol reflux secondary, and 8 times of amount solvents are 2.5 hours for the first time, and 5 times of amount solvents are 1.5 hours for the second time, merge ethanol extract, reclaim ethanol and concentrated, 3000r/min is centrifugal, supernatant and Hirudo liquid are merged, placed 48 hours, in 0 ℃ of-10 ℃ of cold preservation, centrifugal 3000r/min gets supernatant and adds correctives, antiseptic, adds water, stir evenly, leave standstill, filter, fill, sterilization, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03107815 CN1254255C (en) | 2003-01-08 | 2003-03-17 | Oral liquor for curing cerebral hemorrhage and its preparation method by using leach |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03110818.0 | 2003-01-08 | ||
| CN03110818 | 2003-01-08 | ||
| CN 03107815 CN1254255C (en) | 2003-01-08 | 2003-03-17 | Oral liquor for curing cerebral hemorrhage and its preparation method by using leach |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1515285A CN1515285A (en) | 2004-07-28 |
| CN1254255C true CN1254255C (en) | 2006-05-03 |
Family
ID=34276233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03107815 Expired - Lifetime CN1254255C (en) | 2003-01-08 | 2003-03-17 | Oral liquor for curing cerebral hemorrhage and its preparation method by using leach |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1254255C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309932A (en) * | 2016-11-15 | 2017-01-11 | 刘金海 | Traditional Chinese medicine composition for treating cerebral hemorrhage and preparation method thereof |
| CN107213251B (en) * | 2017-06-08 | 2018-07-31 | 广州得效生物科技有限公司 | A kind of Chinese medicine composition and preparation method thereof prevented and/or treat cardiovascular and cerebrovascular disease |
-
2003
- 2003-03-17 CN CN 03107815 patent/CN1254255C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1515285A (en) | 2004-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1628768A (en) | Medicine for treating gout affection and its symptoms | |
| CN1254255C (en) | Oral liquor for curing cerebral hemorrhage and its preparation method by using leach | |
| CN100377731C (en) | Chinese traditional medicine and its preparation method and use | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN101590092B (en) | Traditional Chinese medicine combination for treating leukemia and preparation method thereof | |
| US20230043437A1 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
| CN1081465C (en) | Rhodiola rosea injection for treating angina pectoris of coronary heart disease | |
| CN1292766C (en) | Chinese medicinal preparation for treating viral myocarditis and its making method | |
| CN1072951C (en) | Qingying injection for clearing heat and resisting infection and its preparing process | |
| CN1057928C (en) | Medicine for ulcer and its preparation | |
| CN1302767C (en) | Apoplexy treating injection | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN1264565C (en) | Anti-senility plaster | |
| CN102309550A (en) | Traditional Chinese medicinal aerosol for preventing and treating summer humidity disease and preparation method thereof | |
| CN1283310C (en) | Chinese medicinal preparation for treating coronarg heart disease arrhythmia and its manufacturing process | |
| CN1237991C (en) | Medicine for treating amnesia and dementia | |
| CN1947729A (en) | Traditional Chinese medicine composition for anti-inflammation, preparing method and use thereof | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1265806C (en) | Medicinal composition for treating rheumatism | |
| CN1973867A (en) | Chinese medicine prepn for treating arrhythmia | |
| CN1864717A (en) | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof | |
| CN1528387A (en) | Use of radix rhodiolae for preparing medicine for treating or preventing senile dementia | |
| CN1136900C (en) | Medicine for treating pulmonary tuberculosis and its preparing process | |
| CN102813767A (en) | First-aid drug for treating heatstroke and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060503 |